AAOMC 2024 Annual Partners
We extend our gratitude to our esteemed partners whose unwavering support plays a pivotal role in advancing the American Academy of Orthokeratology & Myopia Control’s mission. These generous contributions enable us to make a significant impact in the field of orthokeratology and myopia control. Together, we are dedicated to shaping a future where vision care reaches new heights.
Founded in 2014, Sydnexis is a privately held, clinical-stage biopharmaceutical company headquartered in Del Mar, California. We are currently evaluating our proprietary eye drop formulation, SYD-101, in a large scale Phase 3 clinical trial. Our mission is to develop a highly differentiated stable, accurate, safe and effective topical eye drop to treat myopia progression in children.